5HJ0 Stock Chart & Stats
€0.30
€0.00(0.00%)
At close: 4:00 PM EDT
€0.30
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.26 - €0.81
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.02M
Enterprise Value-€13.79M
Total Cash (Recent Filing)€21.49M
Total Debt (Recent Filing)€505.00K
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Nov 05, 2026EPS Estimate
-2.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-520.08
Shares Outstanding694,826
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-29.84
Revenue Forecast (FY)€5.97M
Bulls Say, Bears Say
Bulls Say
Focused Medical-device PlatformA focused product addressing severe chronic venous insufficiency gives enVVeno a clearly defined clinical and commercial objective. If VenoValve demonstrates durable clinical value, this specialization could support differentiated positioning in a targeted vascular intervention market.
Very Low LeverageMinimal debt reduces fixed financial obligations and limits the risk that interest or refinancing requirements constrain operations. This provides greater flexibility to direct available capital toward VenoValve development and commercialization while the company remains pre-revenue.
Improving Loss ProfileThe narrowing net loss and improvement in cash burn indicate some progress in cost control, even though the company is not yet profitable. Continued discipline could extend operational capacity and improve the economics of future commercialization if revenue begins to develop.
Bears Say
Pre-revenue Business ModelWith no reported revenue, the company has not yet demonstrated commercial adoption or a recurring source of operating income. This leaves future financial performance highly dependent on successful VenoValve development, regulatory progress, and eventual market acceptance.
Persistent Cash ConsumptionSustained negative operating and free cash flow means the business currently consumes capital rather than generating internally funded growth. Ongoing cash needs can limit strategic flexibility and increase dependence on additional financing before commercialization produces meaningful receipts.
Shrinking Equity BaseThe materially smaller equity base reflects the cumulative impact of ongoing losses and indicates that shareholder capital has been eroded over time. If losses continue, further funding may be required and could increase dilution risk while reducing financial resilience.
enVVeno Medical News
5HJ0 FAQ
What was enVVeno Medical’s price range in the past 12 months?
enVVeno Medical lowest stock price was €0.26 and its highest was €0.81 in the past 12 months.
What is enVVeno Medical’s market cap?
enVVeno Medical’s market cap is €5.02M.
When is enVVeno Medical’s upcoming earnings report date?
enVVeno Medical’s upcoming earnings report date is Nov 05, 2026 which is in 30 days.
How were enVVeno Medical’s earnings last quarter?
enVVeno Medical released its earnings results on Jul 31, 2026. The company reported -€4.786 earnings per share for the quarter, missing the consensus estimate of -€4.18 by -€0.606.
Is enVVeno Medical overvalued?
According to Wall Street analysts enVVeno Medical’s price is currently Overvalued.
Does enVVeno Medical pay dividends?
enVVeno Medical does not currently pay dividends.
What is enVVeno Medical’s EPS estimate?
enVVeno Medical’s EPS estimate is -2.91.
How many shares outstanding does enVVeno Medical have?
enVVeno Medical has 694,826 shares outstanding.
What happened to enVVeno Medical’s price movement after its last earnings report?
enVVeno Medical reported an EPS of -€4.786 in its last earnings report, missing expectations of -€4.18. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of enVVeno Medical?
Currently, no hedge funds are holding shares in DE:5HJ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
enVVeno Medical
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.